Subsequent Events - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended	6 Months Ended
	Jul. 25, 2022	Jul. 20, 2022	Jul. 18, 2022	Oct. 31, 2021	Jun. 30, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Issuance of common stock, value					$ 49	$ 49
Common stock shares issued					48,709,652	48,511,735
Common stock fair value					$ 0.001	$ 0.001
Net proceeds from sale of common stock					$ 242,900
License Agreement
Subsequent Event [Line Items]
Milestone related expenses				$ 10,000	$ 0
Non-refundable upfront license fees paid				$ 800
Subsequent Event | Strategic License and Collaboration Agreement
Subsequent Event [Line Items]
Non-refundable upfront payment		$ 25,000
Maximum Success Payments For Each Product			$ 66,000
Development and commercial milestone payments under collaboration agreement			340,000
Subsequent Event | Strategic License and Collaboration Agreement | Minimum
Subsequent Event [Line Items]
Non-refundable upfront license fees paid			25,000
Subsequent Event | Strategic License and Collaboration Agreement | Maximum
Subsequent Event [Line Items]
Success payments for each product			$ 22,000
Profit share			40.00%
Non-refundable upfront license fees paid			$ 70,000
Subsequent Event | Public offering
Subsequent Event [Line Items]
Shares issued and sold	9,583,334
Common stock shares issued	1,250,000
Common Stock Offering Price Per Share	$ 27.00
Net proceeds from sale of common stock	$ 242,900
Underwriting discounts and commissions	15,500
Offering Costs	$ 300
Subsequent Event | Vertex Pharmaceuticals [Member]
Subsequent Event [Line Items]
Non-refundable upfront payment		$ 25,000
Subsequent Event | Vertex Pharmaceuticals [Member] | Strategic License and Collaboration Agreement | Minimum
Subsequent Event [Line Items]
Profit share			60.00%
Subsequent Event | Vertex Pharmaceuticals [Member] | Stock Purchase Agreement
Subsequent Event [Line Items]
Agreegate purchase price			$ 35,000
Common stock shares issued			1,519,756
Common stock fair value			$ 23.03